# US 11,309,088 B2 · Method, system, and computer readable medium for virtualization of a continuous glucose monitoring trace

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,309,088 B2
- Document ID: US11309088B2
- Status: Granted
- Kind: B2
- Application number: 16/073,920
- Filed: 2017-01-30
- Published: 2019-02-07
- Granted: 2022-04-19
- Earliest claimed: 2016-01-29
- Assignees: University of Virginia Patent Foundation
- Applicants: University of Virginia Patent Foundation
- Inventors: Stephen D. Patek; Marc D. Breton
- Web page: https://patentgrep.com/patent/US11309088B2

## CPC

- G16H 50/50: for simulation or modelling of medical disorders
- G16H 10/60: for patient-specific data, e.g. for electronic patient records
- G16H 40/63: for local operation
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

A method and system use mathematical models and available patient information to virtualize a continuous glucose monitoring trace for a period of time. Such a method and system can generate the virtualized trace when episodic patient data is incomplete. Such a method and system can also rely on self-monitored blood glucose measurement information to improve the virtualized continuous glucose monitoring trace.

## Claims

### Claim 1

A method for titrating insulin therapy for a patient, the method comprising:
estimating, via an estimation module, a patient continuous glucose monitoring trace for a time period using a mathematical model, the mathematical model including a parameter that is representative of an estimated metabolic signal related to blood glucose excursions unexplained by the mathematical model;
obtaining, via a communication module, patient episodic glucose data before the time period and over the time period;
modifying, via an optimization module, the estimated patient continuous glucose monitoring trace for the time period to fit the obtained patient episodic glucose data over the time period using a cost function that penalizes:
deviations of the estimated continuous glucose monitoring trace away from blood glucose samples of the episodic glucose data obtained before and/or during the time period; and
a rate-of-change in the estimated metabolic signal that is greater than a pre-determined rate-of-change; and
titrating, via a controller of an insulin delivery device, at least one of carbohydrate ratios, correction factors, correction thresholds and targets, or basal insulin doses based on the modified estimated patient continuous glucose monitoring trace.

### Claim 2 (depends on 1)

The method of claim 1, comprising:
obtaining at least one of patient biosignals or patient factors; and
wherein the modifying of the estimated patient continuous glucose monitoring trace further fits the obtained at least one of patient biosignals or patient factors.

### Claim 3 (depends on 2)

The method of claim 2, wherein the modifying of the estimated patient continuous glucose monitoring trace uses a higher weight for recent information than less recent information.

### Claim 4 (depends on 1)

The method of claim 1, wherein the estimated patient continuous glucose monitoring trace includes data collected after the time period.

### Claim 5 (depends on 1)

The method of claim 1, comprising:
obtaining patient treatment relevant data;
wherein the modifying of the estimated patient continuous glucose monitoring trace further fits the obtained patient treatment relevant data.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mathematical model used to estimate the patient continuous glucose monitoring trace is individualized to the patient.

### Claim 7

A system for titrating insulin therapy for a patient, the system comprising:
an estimation module configured to estimate a patient continuous glucose monitoring trace for a time period using a mathematical model, the mathematical model including a parameter that is representative of an estimated metabolic signal related to blood glucose excursions unexplained by the mathematical model;
a communications module configured to received patient episodic glucose data before the time period and over the time period from a data source;
an optimization module configured to modify the estimated patient continuous glucose monitoring trace for the time period to fit the obtained patient episodic glucose data over the time period using a cost function that penalizes:
deviations of the estimated continuous glucose monitoring trace away from blood glucose samples of the episodic glucose data obtained before and/or during the time period; and
a rate-of-change in the estimated metabolic signal that is greater than a pre-determined rate-of-change; and
an insulin delivery device controller configured to titrate at least one of carbohydrate ratios, correction factors, correction thresholds and targets, or basal insulin doses based on the modified estimated patient continuous glucose monitoring trace.

### Claim 8 (depends on 7)

The system of claim 7, wherein the communications module is configured to receive at least one of patient biosignals or patient factors; and
wherein the optimization module further fits the obtained at least one of patient biosignals or patient factors.

### Claim 9 (depends on 8)

The system of claim 8, wherein the optimization module uses a higher weight for recent information than less recent information.

### Claim 10 (depends on 7)

The system of claim 7, wherein the estimation module includes data collected after the time period.

### Claim 11 (depends on 7)

The system of claim 7, wherein the communications module is configured to receive patient treatment relevant data; and
wherein the optimization module further fits the obtained patient treatment relevant data.

### Claim 12 (depends on 7)

The system of claim 7, wherein the mathematical model used by the estimation module to estimate the patient continuous glucose monitoring trace is individualized to the patient.